Literature DB >> 3275751

Histopathology of childhood sarcomas, Intergroup Rhabdomyosarcoma Studies I and II: clinicopathologic correlation.

W A Newton1, E H Soule, A B Hamoudi, H M Reiman, H Shimada, M Beltangady, H Maurer.   

Abstract

Histopathologic material from 1,782 patients registered in the Intergroup Rhabdomyosarcoma Study Committee (IRS)-I and -II were reviewed by the IRS Pathology Committee in order to provide a uniform approach to classification and correlate patient survival with tumor type. Categories considered eligible were the four types of rhabdomyosarcoma (RMS) (criteria of Horn and Enterline), extraosseous Ewing's tumor (EOE), and a group of somewhat variable undifferentiated sarcomas designated small round cell sarcoma, type indeterminate (STI). Tumors that were clearly sarcomas but were unclassifiable also were included (NOS). The committee diagnoses were embryonal (Emb) RMS in 877 (54%), alveolar (Alv) RMS in 343 (21%), botryoid (Botr) RMS in 88 (5%), pleomorphic (Pleo) RMS in 11 (1%), STI in 135 (8%), and EOE in 84 (5%). One in nine were mixtures of types, eg, Emb and Alv. Five percent of the sarcomas could not be classified because of inadequate material. In general, there was close agreement (94%) between the review committee and institutional pathologists in the diagnosis of RMS, but not in the specific types, particularly Alv RMS (41%) and STI (36%). This observation is important, since patients with Alv RMS and STI tumors had decreased survival compared with the other histologies. The prognosis varied by histology, with Botr having the best, Alv RMS and STI the worst, and Emb RMS and EOE an intermediate prognosis.

Entities:  

Mesh:

Year:  1988        PMID: 3275751     DOI: 10.1200/JCO.1988.6.1.67

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  31 in total

1.  Myogenic regulatory protein (MyoD1) expression in childhood solid tumors: diagnostic utility in rhabdomyosarcoma.

Authors:  P Dias; D M Parham; D N Shapiro; B L Webber; P J Houghton
Journal:  Am J Pathol       Date:  1990-12       Impact factor: 4.307

2.  Embryonal rhabdomyosarcoma of urinary bladder in an adult patient: an unusual manifestation.

Authors:  Ajay Aggarwal; Vishwajeet Singh; Siddharth Pandey; Rahul Janak Sinha
Journal:  BMJ Case Rep       Date:  2018-04-13

3.  Tumor-specific PAX3-FKHR transcription factor, but not PAX3, activates the platelet-derived growth factor alpha receptor.

Authors:  J A Epstein; B Song; M Lakkis; C Wang
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

4.  Surgical lessons from the Intergroup Rhabdomyosarcoma Study (IRS) pertaining to extremity tumors.

Authors:  W Lawrence; D M Hays; R Heyn; M Beltangady; H M Maurer
Journal:  World J Surg       Date:  1988-10       Impact factor: 3.352

Review 5.  Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies.

Authors:  Suman Malempati; Douglas S Hawkins
Journal:  Pediatr Blood Cancer       Date:  2012-02-29       Impact factor: 3.167

6.  Evolution of Care of Orbital Tumors with Radiation Therapy.

Authors:  Myrsini Ioakeim-Ioannidou; Shannon M MacDonald
Journal:  J Neurol Surg B Skull Base       Date:  2020-08-24

7.  Adult urinary bladder tumors with rhabdomyosarcomatous differentiation: clinical, pathological and immunohistochemical studies.

Authors:  Zhanyong Bing; Paul J Zhang
Journal:  Diagn Pathol       Date:  2011-07-15       Impact factor: 2.644

8.  Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group.

Authors:  Elai Davicioni; Michael J Anderson; Friedrich Graf Finckenstein; James C Lynch; Stephen J Qualman; Hiroyuki Shimada; Deborah E Schofield; Jonathan D Buckley; William H Meyer; Poul H B Sorensen; Timothy J Triche
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

9.  NRF2 orchestrates the redox regulation induced by radiation therapy, sustaining embryonal and alveolar rhabdomyosarcoma cells radioresistance.

Authors:  Francesco Marampon; Silvia Codenotti; Francesca Megiorni; Andrea Del Fattore; Simona Camero; Giovanni Luca Gravina; Claudio Festuccia; Daniela Musio; Francesca De Felice; Valerio Nardone; Anna Natalizia Santoro; Carlo Dominici; Alessandro Fanzani; Luigi Pirtoli; Antonella Fioravanti; Vincenzo Tombolini; Sara Cheleschi; Paolo Tini
Journal:  J Cancer Res Clin Oncol       Date:  2019-01-30       Impact factor: 4.553

Review 10.  Paratesticular rhabdomyosarcoma.

Authors:  J D de Vries
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.